Ovayoza Adeleye
Psychiatry · Natchitoches, LANPI 1538150263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 294 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,099, 6.1 times the $180 reported in 2019.
Across 294 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$791
- Alkermes, Inc.$583
- Otsuka America Pharmaceutical, Inc.$436
- Neurocrine Biosciences, Inc.$380
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$354
- plus $1K from 11 others
What the payments were for
- Food & beverage$4,62397%
- Education$1553%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $1,030 |
| Teva Pharmaceuticals USA, Inc. | 39 | $791 |
| Alkermes, Inc. | 35 | $583 |
| Otsuka America Pharmaceutical, Inc. | 25 | $436 |
| Neurocrine Biosciences, Inc. | 21 | $380 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $354 |
| Lundbeck LLC | 15 | $294 |
| Vanda Pharmaceuticals Inc. | 9 | $202 |
| Johnson & Johnson | 9 | $149 |
| Corium, LLC | 6 | $139 |
| Sunovion Pharmaceuticals Inc. | 9 | $127 |
| Axsome Therapeutics, Inc. | 5 | $72 |
| Merck | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Sanofi Pasteur Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- VRAYLAR$128
- ARISTADA INITIO$125
How this compares
$4,777 in reported general payments places this provider in the 85th percentile of 474 psychiatry providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 28 | $328,321 |
| Invega SustennaPaliperidone Palmitate | 58 | $167,963 |
| Abilify MaintenaAripiprazole | 37 | $74,073 |
| VraylarCariprazine Hcl | 19 | $29,291 |
| Lurasidone Hcl | 33 | $6,274 |
| Clozapine | 15 | $2,372 |
| Aripiprazole | 68 | $1,632 |
| Quetiapine Fumarate | 89 | $1,528 |
| Bupropion XlBupropion Hcl | 55 | $1,287 |
| Duloxetine Hcl | 70 | $1,198 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $1,169 |
| Atomoxetine Hcl | 12 | $1,075 |
| Benztropine Mesylate | 57 | $1,053 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 47 | $1,040 |
| Ziprasidone Hcl | 21 | $1,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $380 | $328,32128 claims |
| Johnson & JohnsonInvega Sustenna | $149 | $167,96358 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $436 | $74,07337 claims |
| AbbVieVraylar | $1,030 | $29,29119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Natchitoches
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
- Andrew MorsonNew Orleans$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.